Scientists continue to explore the therapeutic possibilities of psilocybín, the psychoactive compound found in magické huby, and a nová štúdia suggests it may hold promise for people living with post-treatment Lyme disease (PTLD).
Researchers at Univerzita Johnsa Hopkinsa recently published a pilot study in Vedecké správy examining whether psilocybin-assisted therapy could help alleviate the persistent symptoms many patients experience after standard Lyme disease treatment.
The early results point to meaningful improvements in symptoms and quality of life lasting up to six months after treatment. While the study was small and exploratory, the findings have generated interest in the potential role psychedelics may play in addressing conditions that currently have few treatment options.
Understanding Lyme Disease
To appreciate why this research matters, it helps to understand what Lyme disease is and how it can affect the body.
Lyme disease is an infectious illness caused by the bacterium Borrelia burgdorferi. The bacteria are transmitted to humans through the bite of infected ticks, most commonly black-legged ticks (often called deer ticks). Lyme disease is the most widespread vector-borne disease in both the United States and Europe.
Early symptoms can resemble the flu and may include fever, fatigue, muscle aches, headache, and swollen lymph nodes. One of the most recognizable signs is a distinctive “bull’s-eye” rash called erythema migrans, although not everyone develops it.
If diagnosed early, Lyme disease is usually treated successfully with antibiotics. However, the infection can affect multiple systems in the body. In some cases it spreads to joints, the nervous system, or the heart. Neurological involvement may lead to problems such as memory difficulties, headaches, or nerve pain.
For many patients, antibiotic therapy resolves the infection and symptoms fade. Yet an estimated 10–20% of people continue to experience health problems even after treatment. This condition is known as post-treatment Lyme disease (PTLD).
What Is Post-Treatment Lyme Disease?
People living with PTLD report a range of ongoing symptoms that can persist for months or years. These often include:
- Persistent fatigue
- Joint or muscle pain
- Cognitive difficulties sometimes described as “brain fog”
- Sleep disturbances
- Mood changes such as anxiety or depression
- Reduced overall quality of life
Researchers are still working to understand why PTLD occurs. Some theories suggest lingering immune system dysregulation or inflammation following infection. Others point to long-term neurological effects.
At present, there are no widely accepted treatments specifically for PTLD, which leaves many patients searching for ways to manage symptoms.
Investigating Psilocybin as a Potential Therapy
The new study from Johns Hopkins explored whether psilocybin-assisted therapy might help improve well-being in people living with PTLD.
Psilocybin occurs naturally in several species of psychoactive mushrooms, often referred to as magické huby. Once consumed, the compound is converted in the body to psilocin, which interacts with serotonin receptors in the brain.
Over the past decade, psilocybin has been widely studied for its possible benefits in areas such as depression, addiction, anxiety, and emotional distress related to serious illness.
The researchers wanted to see whether the compound, when combined with psychological support, could also help patients experiencing long-term symptoms associated with Lyme disease.
Inside the Study
The pilot trial involved 20 participants diagnosed with PTLD. Over the course of an eight-week intervention period, they received two low-to-moderate doses of psilocybin along with structured psychological support.
Before their first dosing session, participants attended standardised psychoeducation meetings where they learned about the effects of psilocybin and discussed what they might experience during sessions.
They also completed a life review process, reflecting on their personal history with Lyme disease as well as other significant life events — including trauma, relationships, and work experiences — that could influence their health.
The study schedule included two psilocybin sessions:
- Week 4: Participants received their first dose of 15 mg
- Two weeks later: Most participants received a 25 mg dose, while some received another 15 mg depending on tolerance
“After each psilocybin session, participants completed a follow-up integration meeting within 3 days to assess their mental status and document any adverse events. Weekly meetings with facilitators were conducted through week 8 to discuss the contents of participants’ psilocybin session and to monitor their overall progress,” the study author explains.
Integration sessions are commonly used in psychedelic-assisted therapy to help participants reflect on their experiences and incorporate insights into daily life.
Improvements in Symptoms and Quality of Life
By the end of the study period and during follow-up assessments, researchers observed notable improvements across several measures.
Participants reported reduced overall symptom burden and improved quality of life, with benefits persisting for up to six months after the final dose.
At the six-month mark, the study recorded a 40% reduction in symptom burden compared with baseline.
Both mental and physical quality-of-life scores increased by approximately 13%, while measures related to:
- depresia
- únava
- sleep disturbances
- pain
also showed meaningful improvement.
These changes remained better than baseline levels during all follow-up assessments at one, three, and six months after treatment.
Safety and Side Effects
The treatment protocol was reported to be safe and well-tolerated among participants.
No serious adverse events occurred during the trial. The most frequently reported side effects were temporary and included:
- elevated blood pressure
- headaches
- increased heart rate
These effects occurred during or shortly after psilocybin sessions and resolved without long-term complications.
What the Researchers Concluded
Because the trial involved a relatively small group and lacked a placebo control, the results are considered preliminary. Larger, randomized clinical trials will be needed to determine whether psilocybin therapy can reliably help patients with PTLD.
Still, the researchers see the results as encouraging.
They concluded that the findings were “sufficiently positive to encourage additional randomised controlled research with psilocybin in patients with PTLD”.
The Expanding Field of Psilocybin Research
Interest in terapia psilocybínom has grown rapidly in recent years. As our regular readers will know, clinical studies have examined its potential role in treating a variety of conditions, including:
- veľká depresia
- substance use disorders such as opioid addiction
- anxiety related to serious illness
- age-related cognitive decline
- metabolic conditions such as fatty liver disease
The new research adds post-treatment Lyme disease to the list of areas scientists are beginning to investigate.
For individuals living with PTLD — a condition that can profoundly affect daily functioning — even early signs of potential relief offer a reason for cautious optimism.
As larger studies move forward, researchers hope to better understand how psilocybin and magic mushroom compounds interact with the brain and immune system, and whether these effects could translate into new therapeutic options for chronic conditions that currently lack effective treatments.
